Skip to main content

Table 5 Odds ratios (OR) and corresponding 95% confidence intervals (CI) for TRG1 and tumor downstaging according to selected characteristics

From: Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study

  TRG 1 OR (95% CI)a Downstaging OR (95% CI)a
  n (%) n (%)
Sex
 Man 13 (26.0) Reference 34 (70.8) Reference
 Woman 7 (26.9) 1.67 (0.60–4.62) 18 (72.0) 0.90 (0.21–3.88)
Age (years)
 < 55 5 (29.4) Reference 12 (70.6) Reference
 55–64 5 (18.5) 0.36 (0.10–1.27) 14 (56.0) 0.37 (0.07–1.99)
 65–74 6 (31.6) 1.01 (0.26–3.85) 16 (84.2) 2.93 (0.40–21.37)
 ≥ 75 4 (30.8) 0.85 (0.20–3.56) 10 (83.3) 2.75 (0.34–22.48)
Distance EAS (mm)
 < 60 9 (23.7) Reference 29 (80.6) Reference
 ≥ 60 8 (27.6) 0.88 (0.30–2.55) 17 (58.6) 0.12 (0.02–0.69)
 Unknown 3 (33.3) 1.026 (0.22–7.12) 6 (75.0) 0.15 (0.01–2.43)
cT
 cT2 2 (40.0) Reference 3 (100.0) -
 cT3 17 (27.0) 0.29 (0.02–4.14) 42 (67.7) -
 cT4 1 (12.5) 0.29 (0.02–5.68) 7 (87.5) -
cN
 cN0 4 (33.3) Reference 8 (66.7) Reference
 cN1 10 (25.6) 0.59 (0.16–2.23) 25 (67.6) 0.39 (0.06–2.60)
 cN2 6 (24.0) 0.77 (0.18–3.34) 19 (79.2) 1.14 (0.17–7.82)
MRF involvment
 No 6 (17.7) Reference 31 (79.5) Reference
 Yes 14 (33.3) 0.34 (0.11–1.01) 21 (61.8) 0.29 (0.07–1.18)
Single dose intensity
 2.1 3 (18.8) Reference 12 (80.0) Reference
 2.16 9 (37.5) 1.45 (0.36–5.84) 15 (62.5) 0.16 (0.02–1.47)
 ≥ 2.2 8 (22.2) 1.45 (0.39–5.38) 25 (73.5) 1.14 (0.14–9.25)
  1. aAdjusted for all variables reported in the table